Literature DB >> 2068108

p53 in chronic myelogenous leukemia in acute phase.

E Feinstein1, G Cimino, R P Gale, G Alimena, R Berthier, K Kishi, J Goldman, A Zaccaria, A Berrebi, E Canaani.   

Abstract

All patients with chronic myelogenous leukemia (CML) undergo clinical transition from chronic to acute phase. This transition is often associated with deletion of the short arm of chromosome 17 in the form of the i(17q) aberration. Since the p53 gene is a suppressor gene and is located on 17p13, we examined the possibility that it is inactivated during progression of CML. Therefore, we studied the structure and expression of p53 in the leukemic cells of a large number of CML patients in acute phase. We found that although the gene is rarely rearranged, one p53 allele is completely deleted in patients with the i(17q) aberration as well as in some patients who do not show karyotypic changes. In all of these patients the remaining allele is inactivated through loss of expression, rearrangement, or point mutation. Detailed analysis of some patients who carry both p53 alleles indicated neither loss of expression nor structural alterations. It appears that p53 loss of function is associated with progression of around 25% of CML patients.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2068108      PMCID: PMC52069          DOI: 10.1073/pnas.88.14.6293

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  35 in total

1.  Chromosome studies on normal and leukemic human leukocytes.

Authors:  P C NOWELL; D A HUNGERFORD
Journal:  J Natl Cancer Inst       Date:  1960-07       Impact factor: 13.506

Review 2.  Chronic myelogenous leukemia: recent advances.

Authors:  R E Champlin; D W Golde
Journal:  Blood       Date:  1985-05       Impact factor: 22.113

Review 3.  Chromosome abnormalities in malignant hematologic diseases.

Authors:  J D Rowley; J R Testa
Journal:  Adv Cancer Res       Date:  1982       Impact factor: 6.242

4.  Rearrangements of the cellular p53 gene in erythroleukaemic cells transformed by Friend virus.

Authors:  M Mowat; A Cheng; N Kimura; A Bernstein; S Benchimol
Journal:  Nature       Date:  1985 Apr 18-24       Impact factor: 49.962

5.  The human cellular abl gene product in the chronic myelogenous leukemia cell line K562 has an associated tyrosine protein kinase activity.

Authors:  W Kloetzer; R Kurzrock; L Smith; M Talpaz; M Spiller; J Gutterman; R Arlinghaus
Journal:  Virology       Date:  1985-01-30       Impact factor: 3.616

6.  An 8-kilobase abl RNA transcript in chronic myelogenous leukemia.

Authors:  R P Gale; E Canaani
Journal:  Proc Natl Acad Sci U S A       Date:  1984-09       Impact factor: 11.205

7.  Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22.

Authors:  J Groffen; J R Stephenson; N Heisterkamp; A de Klein; C R Bartram; G Grosveld
Journal:  Cell       Date:  1984-01       Impact factor: 41.582

8.  Analysis of BCR-ABL mRNA in chronic myelogenous leukemia patients and identification of a new BCR-related sequence in human DNA.

Authors:  C Marcelle; R P Gale; M Prokocimer; A Berrebi; H Merle-Beral; E Canaani
Journal:  Genes Chromosomes Cancer       Date:  1989-11       Impact factor: 5.006

9.  Purification of mouse immunoglobulin heavy-chain messenger RNAs from total myeloma tumor RNA.

Authors:  C Auffray; F Rougeon
Journal:  Eur J Biochem       Date:  1980-06

10.  An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity.

Authors:  J B Konopka; S M Watanabe; O N Witte
Journal:  Cell       Date:  1984-07       Impact factor: 41.582

View more
  51 in total

1.  p53 expression in lymphatic malignancies.

Authors:  Y Soini; P Pääkkö; M Alavaikko; K Vähäkangas
Journal:  J Clin Pathol       Date:  1992-11       Impact factor: 3.411

2.  Ikaros induces quiescence and T-cell differentiation in a leukemia cell line.

Authors:  Katie L Kathrein; Rachelle Lorenz; Angela Minniti Innes; Erin Griffiths; Susan Winandy
Journal:  Mol Cell Biol       Date:  2005-03       Impact factor: 4.272

Review 3.  Targeting the leukemic stem cell: the Holy Grail of leukemia therapy.

Authors:  N Misaghian; G Ligresti; L S Steelman; F E Bertrand; J Bäsecke; M Libra; F Nicoletti; F Stivala; M Milella; A Tafuri; M Cervello; A M Martelli; J A McCubrey
Journal:  Leukemia       Date:  2008-09-18       Impact factor: 11.528

4.  Combination treatment in vitro with Nutlin, a small-molecule antagonist of MDM2, and pegylated interferon-α 2a specifically targets JAK2V617F-positive polycythemia vera cells.

Authors:  Min Lu; Xiaoli Wang; Yan Li; Joseph Tripodi; Goar Mosoyan; John Mascarenhas; Marina Kremyanskaya; Vesna Najfeld; Ronald Hoffman
Journal:  Blood       Date:  2012-08-07       Impact factor: 22.113

5.  Loss of p53 impedes the antileukemic response to BCR-ABL inhibition.

Authors:  Hans-Guido Wendel; Elisa de Stanchina; Enriqué Cepero; Sagarika Ray; Michael Emig; Jordan S Fridman; Darren R Veach; William G Bornmann; Bayard Clarkson; W Richard McCombie; Scott C Kogan; Andreas Hochhaus; Scott W Lowe
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-01       Impact factor: 11.205

6.  Second generation tyrosine kinase inhibitors prevent disease progression in high-risk (high CIP2A) chronic myeloid leukaemia patients.

Authors:  C M Lucas; R J Harris; A K Holcroft; L J Scott; N Carmell; E McDonald; F Polydoros; R E Clark
Journal:  Leukemia       Date:  2015-03-13       Impact factor: 11.528

7.  Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice.

Authors:  Yiguo Hu; Sarah Swerdlow; Theodore M Duffy; Roberto Weinmann; Francis Y Lee; Shaoguang Li
Journal:  Proc Natl Acad Sci U S A       Date:  2006-10-31       Impact factor: 11.205

8.  High levels of the BCR/ABL oncoprotein are required for the MAPK-hnRNP-E2 dependent suppression of C/EBPalpha-driven myeloid differentiation.

Authors:  Ji Suk Chang; Ramasamy Santhanam; Rossana Trotta; Paolo Neviani; Anna M Eiring; Edward Briercheck; Mattia Ronchetti; Denis C Roy; Bruno Calabretta; Michael A Caligiuri; Danilo Perrotti
Journal:  Blood       Date:  2007-05-02       Impact factor: 22.113

9.  P53 mutation in acute T cell lymphoblastic leukemia is of somatic origin and is stable during establishment of T cell acute lymphoblastic leukemia cell lines.

Authors:  J Yeargin; J Cheng; A L Yu; R Gjerset; M Bogart; M Haas
Journal:  J Clin Invest       Date:  1993-05       Impact factor: 14.808

10.  Individual telomere lengths in chronic myeloid leukemia.

Authors:  Oumar Samassekou; Aimé Ntwari; Josée Hébert; Ju Yan
Journal:  Neoplasia       Date:  2009-11       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.